Citius oncology, inc.CTOR.US Overview
US StockHealthcare
(No presentation for CTOR)
CTOR Overall Performance
CTOR AI Analysis & Strategy
CTOR Recent Performance
-1.82%
Citius oncology, inc.
0.81%
Avg of Sector
-1.14%
S&P500
CTOR PowerScanner
CTOR Key Information
CTOR Valuation Metrics
CTOR Earnings Table
CTOR Profile
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.